Please try another search
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Christopher J. Calise | 50 | 2017 | Independent Director |
Evren Alici | - | 2022 | Member of Scientific & Clinical Advisory Board |
Philippe Deschamps | 62 | 2022 | Independent Director |
Tara Maria DeSilva | 55 | 2022 | Independent Director |
David Mehalick | 55 | 2016 | Co-Founder, Chairman of the Board, CEO & President |
Arnika Kathleen Wagner | - | 2022 | Member of Scientific & Clinical Advisory Board |
Hans-Gustaf Ljunggren | - | 2022 | Member of Scientific & Clinical Advisory Board |
Eugene Z. Salkind | 70 | 2022 | Independent Director |
Daniel Alexander Yerace | 41 | 2021 | Co-Founder, VP of Operations & Director |
Christopher Patrick Cochran | 54 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review